Navigation Links
Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
Date:6/24/2011

SAN DIEGO and INDIANAPOLIS, June 24, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from an analysis designed to evaluate the cost-effectiveness of insulin lispro mix 75/25 and insulin lispro mix 50/50 versus long-acting insulin analog (LAIA).

The analysis indicated that for patients with type 2 diabetes who do not experience frequent hypoglycemia, insulin lispro premixed insulin analogs are likely to be cost-effective when compared to LAIA in the long-term treatment of type 2 diabetes. The results were presented today at the Association's 71st Scientific Sessions in San Diego, CA. The study also will be featured at the President's Poster Session, a showcase featuring 100 outstanding posters selected by the Scientific Sessions Meeting Planning Committee.

The analysis further quantified a recent meta-analysis conducted by the Agency for Healthcare Research and Quality (AHRQ), which assessed the relative effectiveness and safety of premixed analog insulin and LAIA, finding that premixed insulin analogs may provide tighter glycemic control than long-acting alternatives.

A validated diabetes model was used to compare the cost effectiveness of insulin lispro premixed insulin analogs versus LAIA from a U.S. healthcare payer perspective.

Insulin lispro premixed insulin analogs were associated with improvements in both life expectancy (+0.07 and +0.09 years, respectively) and quality-adjusted life expectancy (+0.07 quality-adjusted life years [QALYs] and +0.08 QALYs, respectively) when compared with LAIA. These clinical benefits were accompanied by increases in direct lifetime costs of $1,724 and $1,720 relative to LAIA, yielding incremental cost-effectiveness ratios of $28,580 and $23,150 per QALY gained for the premixed insulin analogs versus LAIA, respectively.

To calculate the costs, the base case analysis was
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... the "Infectious Disease Diagnostics Market by Product, Application, ... report to their offering. , The infectious ... of 7.9% to reach $18,156.2 million by 2019 from ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... NEW ORLEANS , May 3 ... developing novel catheter-mounted digital imaging devices, today announced five ... Retroscope® during colonoscopy procedures increases detection of adenomas and ... years of experience, were able to detect adenomas of ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) today announced that it will ... Panel meeting on Monday, May 10, 2010 at ... Don Bailey , President and Chief Executive Officer; Steve Cartt ... Chief Science Officer; and Dr. Jason Zielonka , Senior Vice President and ...
Cached Medicine Technology:Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 2Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 3Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 4Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 5Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 6Questcor to Discuss Results From FDA Panel Meeting 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... HIV/AIDS Atlas , , WASHINGTON, June 22 The ... ( http://www.MapHIV.org ) that highlights the ... States. The Atlas makes information on HIV/AIDS prevalence rates ... a comprehensive picture of the varying intensity of the epidemic ...
... to small increased chances of trouble, research shows , MONDAY, ... double the risk of kidney stones, though the actual odds ... Roux-en-Y, the most common type of gastric bypass surgery, may ... developing the urinary tract disorder usually caused by oxalate in ...
... 22 MUSCLEPHARM(R) LLC, the rising star of the ... product launch through each of Vitamin Shoppe,s 400+ locations ... this nationwide launch of our entire line of products," ... available to athletes in nearly every neighborhood across the ...
... successful completion of the MyCopy pilot project, the specialist ... extended this eBook service to all academic libraries in ... Collections. All registered library patrons will be able to ... for their personal use by clicking on a button ...
... , , HARRISBURG, Pa., June 22 In an ... use on their unborn babies, the Pennsylvania Department of Health ... a new smoking cessation campaign to target the 28 percent ... state. , , "More than one-quarter of expectant ...
... Supreme Court Confirmation Hearings Consider Impact on All Pregnant Women ... for Pregnant Women (NAPW) today released to the public a ... Committee of the United States Senate requesting that the Committee ... Is there a point in pregnancy when you believe ...
Cached Medicine News:Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 2Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 3Health News:Common Weight-Loss Surgery May Double Risk of Kidney Stones 2Health News:MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang! 2Health News:Springer launches MyCopy service for eBook users 2Health News:State Launches New Campaign to Help Pregnant Smokers Go Tobacco-Free 2Health News:Dismantling Roe v. Wade Would Affect All Pregnant Women 2Health News:Dismantling Roe v. Wade Would Affect All Pregnant Women 3
For the quantitative determination of uric acid in serum....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: